Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

A. P. Kudelka, C. F. Verschraegen, T. Levy, C. L. Edwards, A. Fishman, R. S. Freedman, Alan L. Kaplan, D. G. Kieback, R. Mante, K. Ende, M. Steger, J. J. Kavanagh

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance states was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.

Original languageEnglish (US)
Pages (from-to)398-401
Number of pages4
JournalAnti-Cancer Drugs
Volume7
Issue number4
DOIs
StatePublished - 1996

Keywords

  • Cervix cancer
  • Docetaxel
  • Granulocyte colony stimulating factor

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix'. Together they form a unique fingerprint.

Cite this